Bortezomib-induced Posterior Reversible Encephalopathy Syndrome in a Patient with Newly Diagnosed Multiple Myeloma

被引：14

作者：

Oshikawa, Gaku ^{[1
]}

Kojima, Akira ^{[1
]}

Doki, Noriko ^{[1
]}

Kobayashi, Takeshi ^{[1
]}

Kakihana, Kazuhiko ^{[1
]}

Tsuda, Hiromasa ^{[2
]}

Endo, Ikuyo ^{[3
]}

Kamata, Noriko ^{[3
]}

Ohashi, Kazuteru ^{[1
]}

Sakamaki, Hisashi ^{[1
]}

机构：

[1] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Div Hematol, Komae, Tokyo, Japan

[2] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Div Neurol, Komae, Tokyo, Japan

[3] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Div Radiol, Komae, Tokyo, Japan

来源：

INTERNAL MEDICINE | 2013年 / 52卷 / 01期

关键词：

PRES; bortezomib; multiple myeloma; LEUKOENCEPHALOPATHY SYNDROME; DEXAMETHASONE; MANAGEMENT;

D O I：

10.2169/internalmedicine.52.8799

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Posterior reversible encephalopathy syndrome (PRES) is a known but extremely rare side effect of bortezomib therapy. An unusual case of PRES possibly caused by bortezomib during induction treatment in a patient with multiple myeloma is reported. The patient experienced neither hypertensive crisis nor uremic encephalopathy at the onset of PRES, which are both well-known etiologies of PRES. The patient's PRES-related symptoms resolved completely after discontinuation of bortezomib and administration of a bulk dose of corticosteroids. The importance of early recognition of this potential neurological complication must be emphasized because this new drug is being increasingly prescribed.

引用

页码：111 / 114

页数：4

共 13 条

[1] Posterior reversible encephalopathy syndrome following chemotherapy with oxaliplatin and a fluoropyrimidine: A case report and literature review [J].

Femia, Giuseppe ;

Hardy, Todd A. ;

Spies, Judith M. ;

Horvath, Lisa G. .

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2012, 8 (02) :115-122

[2] Posterior Reversible Encephalopathy Syndrome: A Review [J].

Feske, Steven K. .

SEMINARS IN NEUROLOGY, 2011, 31 (02) :202-215

[3] A reversible posterior leukoencephalopathy syndrome [J].

Hinchey, J ;

Chaves, C ;

Appignani, B ;

Breen, J ;

Pao, L ;

Wang, A ;

Pessin, MS ;

Lamy, C ;

Mas, JL ;

Caplan, LR .

NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (08) :494-500

[4] Reversible posterior leukoencephalopathy syndrome - What have we learned in the last 10 years? [J].

Hinchey, Judith A. .

ARCHIVES OF NEUROLOGY, 2008, 65 (02) :175-176

[5] Dexamethasone-induced posterior reversible encephalopathy syndrome [J].

Irvin, William ;

MacDonald, GiGi ;

Smith, J. Keith ;

Kim, William Y. .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (17) :2484-2486

[6] Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma [J].

Jagannath, S ;

Durie, BGM ;

Wolf, J ;

Camacho, E ;

Irwin, D ;

Lutzky, J ;

McKinley, M ;

Gabayan, E ;

Mazumder, A ;

Schenkein, D ;

Crowley, J .

BRITISH JOURNAL OF HAEMATOLOGY, 2005, 129 (06) :776-783

[7] Management Strategies for Relapsed/Refractory Multiple Myeloma: Current Clinical Perspectives [J].

Jakubowiak, Andrzej .

SEMINARS IN HEMATOLOGY, 2012, 49 (03) :S16-S32

[8]

Kager LM, 2009, BMJ CASE REP, pbcr06

[9]

Kelly Kevin, 2008, Br J Haematol, V141, P566, DOI 10.1111/j.1365-2141.2008.07088.x

[10] Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies [J].

Orlowski, RZ ;

Voorhees, PM ;

Garcia, RA ;

Hall, MD ;

Kudrik, FJ ;

Allred, T ;

Johri, AR ;

Jones, PE ;

Ivanova, A ;

Van Deventer, HW ;

Gabriel, DA ;

Shea, TC ;

Mitchell, BS ;

Adams, J ;

Esseltine, DL ;

Trehu, EG ;

Green, M ;

Lehman, MJ ;

Natoli, S ;

Collins, JM ;

Lindley, CM ;

Dees, EC .

BLOOD, 2005, 105 (08) :3058-3065

← 1 2 →